COMPARISON OF THE EFFICACY AND SAFETY OF CEFTIBUTEN AND CEFACLOR IN THE TREATMENT OF PNEUMONIA AND BRONCHIECTASIS

In a multicentre, international study of 187 adult patients with bacte rial pneumonia or bronchiectasis, the safety and efficacy of a regimen of 200 mg ceftibuten administered twice-daily was compared with cefac lor given in a dosage of 500 mg three times a day. Of the 94 evaluable patients, 66 received ceftibuten and 28 received cefaclor. The overal l bacteriological response was similar in the two treatment groups wit h elimination of the original pathogen in 91% and 89% of the patients receiving ceftibuten and cefaclor, respectively. The overall clinical response mirrored the bacteriological results with a successful clinic al outcome in 92% of ceftibuten-treated patients compared with 93% in patients receiving cefaclor. Adverse experiences were, in general, few and mild, being reported in 8% and 17% of patients receiving ceftibut en and cefaclor, respectively.